EUCTR2016-000064-42-CZ进行中（未招募）1 期
Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men or women 18 to 75 years of age at the time of informed consent
- •Confirmed diagnosis of RA according to 2010 American College of
- •Rheumatology (ACR)/The European League Against Rheumatism
- •(EULAR) RA classification criteria of at least 6 months duration
- •Positive RF and/or anti-CCP (anti-cyclic citrullinated peptide)
- •Persistently active disease defined as = 6 swollen joints (of 66
- •counted) and = 6 tender joints (of 68 counted)
- •hsCRP = 3 mg/L
- •Treatment for = 12 weeks with 10 to 25 mg/week MTX at a stable dose
- •for at least 4 weeks prior to dosing with the IMP and maintained
- •throughout the trial
- •Women of childbearing potential must use a highly effective method of
- •contraception combined with one supplementary barrier method for 4
- •weeks prior to randomization, throughout the trial, and for 90 days after
- •the last dose of IMP. For the purposes of this trial:
- •o Females who are postmenopausal (age-related amenorrhea = 12
- •consecutive months and increased follicle-stimulating hormone [FSH] >
- •40 mIU/mL), or who have undergone hysterectomy or bilateral
- •oophorectomy are exempt from pregnancy testing. If necessary to
- •confirm postmenopausal status, an FSH will be drawn at Screening
- •oThe definition of highly effective contraception includes:
- •-combined (estrogen and progestogen containing) hormonal
- •contraception associated with inhibition of ovulation; oral, intravaginal
- •or transdermal
- •-progestogen-only hormonal contraception associated with inhibition of
- •ovulation; oral, injectable, implantable
- •-intrauterine device (IUD)
- •-intrauterine hormone-releasing system (IUS)
- •-bilateral tubal occlusion
- •-vasectomized partner
- •-sexual abstinence
- •oSupplementary barrier methods include:
- •-male or female condom with or without spermicide
- •-cap, diaphragm or sponge with spermicide
- •Women of childbearing potential must have a negative serum
- •pregnancy test at the Screening Visit and a negative urine pregnancy
- •test at Day 1/randomization before dosing.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •Use of oral corticosteroids > 10 mg daily prednisone equivalent, use of injectable corticosteroids, or change in dose of corticosteroids within 2 weeks prior to Screening or during Screening
- •Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to Screening
- •Treatment with tofacitinib, other BTK inhibitors, or a biologic disease-modifying antirheumatic drug (DMARD; eg, anti-tumor necrosis factor alpha [anti-TNF-a], tocilizumab [anti-interleukin-6 receptor], abatacept [CTLA4-Fc]), or other immunosuppressive drugs(sulfasalazine would be acceptable at a stable dose) other than methotrexate within 3 months prior to Screening or during Screening
- •Treatment with anti-CD20 therapy (eg, rituximab) within 12 months prior to Screening or during Screening
- •Immunologic disorder other than RA, with the exception of secondary Sjogren’s syndrome associated with RA, and well-controlled diabetes or thyroid disorder, or any other condition requiring oral, intravenous, intramuscular, or intra-articular corticosteroid therapy
- •Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- •Active, clinically significant, viral, bacterial, or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks of Screening or during Screening, or completion of oral anti-infectives within 2 weeks before or during Screening, or a history of recurrent infections (ie, 3 or more of the same type of infection in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary.
- •History of or positive testing for human immunodeficiency virus (HIV), hepatitis C antibody and/or polymerase chain reaction, hepatitis B surface antigen (HBsAg) (+) and/or hepatitis B core total, and/or IgM antibody (+) at Screening.
- •History of or current diagnosis of active tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of the Screening Visit of a positive TB skin test with purified protein derivative with induration = 5 mm, a positive QuantiFERON®-TB test or positive or borderline T-SPOT [Elispot] test); or positive QuantiFERON-TB test at Screening. Subjects with documented completed appropriate LTBI treatment would not be excluded and are not required to be tested.
- •o Subjects with current household contacts with active TB will also be excluded.
- •o Indeterminate QuantiFERON-TB or T-SPOT tests may be repeated once, and will be considered positive if retest results are positive or indeterminate.
- •History of cancer, except adequately treated basal cell or squamous cell carcinomas of the skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured > 5 years.
- •Clinically significant abnormality on ECG, or an active infective process or any other clinically significant abnormality on Screening chest X-ray (CXR) taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been taken within the previous 3 months and results are available and normal, the CXR does not need to be carried out
- •B cell (CD19) count < 50% of the lower limit of normal at Screening
- •Significant cytopenia including ne
研究者
相似试验
进行中（未招募）
1 期
Safety and Efficacy study of M2951 in Subjects with Rheumatoid ArthritisMedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-000064-42-SKMerck KGaA65
进行中（未招募）
1 期
Safety and Efficacy study of M2951 in Subjects with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2016-000064-42-BGMerck KGaA65
进行中（未招募）
1 期
Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy - N/AMedDRA version: 19.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-000064-42-HUMerck KGaA65
终止
2 期
Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Trial to determine the safety and efficacy of Vitamin D3 in preventing the risk of MS in Patients with a first demyelinating event.Clinically Isolated Syndrome - those who have experienced only one demyelinating event and are yet to receive a diagnosis of clinically definite Multiple Sclerosis (MS).Neurological - Multiple sclerosisACTRN12612001160820MS Research Australia202
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate Crohn's diseaseCrohn’s DiseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-001892-30-BEGalapagos NV120